A study on serum IgE and clinical symptomatology of atopy in patients suffering from the lysosomal storage disorder Fabry disease

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 6, 2008, Pages 692-695

  Mohrenschlager M ^a   Ollert, M ^a   Ring, J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

galactosidase A deficiency; Allergic asthma; Allergic rhinoconjunctivitis; Atopic eczema; Enzyme replacement therapy; Fabry disease; Immunoglobulin E; Intracellular antigen processing; Lysosomal storage disorder; Lysosome

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; GENZYME; IMMUNOGLOBULIN E;

ADULT; AGED; ALLERGIC ASTHMA; ANTIBODY PRODUCTION; ANTIGEN DETECTION; ARTICLE; ATOPIC DERMATITIS; ATOPY; CLINICAL ARTICLE; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HAY FEVER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LYSOSOME; LYSOSOME STORAGE DISEASE; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SKIN DEFECT; SYMPTOMATOLOGY;

ADULT; AGED; DERMATITIS, ATOPIC; FABRY DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 43649084691     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02638.x     Document Type: Article

References (24)

1. Chapman HA. Endosomal proteolysis and MHC class II function. Curr Opin Immunol 1998; 10: 93-102.
2. Nakagawa TY, Rudensky AY. The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation. Immunol Rev 1999; 172: 121-129.
3. Pieters J. MHC class II-restricted antigen processing and presentation. Adv Immunol 2000; 75: 159-208.
4. Ring J. Atopy: Condition, disease, or syndrome? In: Ring J, Przybilla B, Ruzicka T, eds. Handbook of Atopic Eczema. Springer, Berlin, 2006: 3-9.
5. Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338-346.
6. Dobyns WB, Filauro A, Tomson B et al. Inheritance of most X-linked traits is not dominant or recessive, just X-linked. Am J Med Genet A 2004; 129: 136-143.
7. Möhrenschlager M, Ring J, Abeck D. Skin manifestations of Fabry disease. JAMA 2001; 286: 1315.
8. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL Laster L. Enzymatic defect in Fabry's disease: Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-1167.
9. Möhrenschlager M, Braun-Falco M, Ring J, Abeck D. Fabry disease. Recognition and management of cutaneous manifestations. Am J Clin Dermatol 2003; 4: 189-196.
10. Möhrenschlager M, Henkel V, Ring J. Angiokeratomas, Fabry disease and enzyme replacement therapy: Still a challenge. Br J Dermatol 2005; 152: 177-178.
11. Möhrenschlager M, Henkel V, Ring J. Fabry disease: More than angiokeratomas. Arch Dermatol 2004; 140: 1526-1528.
12. Möhrenschlager M, Ring J, Abeck D. Options in the treatment of Fabry disease. Ped Dermatol 2003; 20: 373-374.
13. International Study of Asthma and Allergies in Childhood. Manual, 2nd edn. Auckland, New Zealand, Münster, Germany, 1993.
14. Zetterström O, Johansson SGO. IgE concentrations measured by PRIST in serum of healthy adults and in patients with respiratory allergy. Allergy 1981; 36: 537-547.
15. Dinmezel S, Ogus C, Erengin H, Cilli A, Ozbudak O, Ozdemir T. The prevalence of asthma, allergic rhinitis, and atopy in Antalya, Turkey. Allergy Asthma Proc 2005; 26: 403-409.
16. Dik N, Anthonisen NR, Manfrede J, Roos LL. Physician-diagnosed asthma and allergic rhinitis in Manitoba: 1985-98. Ann Allergy Asthma Immunol 2006; 96: 69-75.
17. Filipiak B, Heinrich J, Schäfer T, Ring J, Wichmann HE. Farming, life style and atopy in adults from southern Germany - results from MONICA/KORA study Augsburg. Clin Exp Allergy 2001; 31: 829-838.
18. Schäfer T, Heinrich J, Böhler E et al. Allergien bei Erwachsenen. Gesundheitswesen 2005; 67 (Suppl. 1): S187-S192.
19. Ring J. Allergy in Practice. Springer, Heidelberg, 2005.
20. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy of Fabry's disease. N Engl J Med 2001; 345: 9-16.
21. Maier E, Osterrieder S, Whybra C et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatrica 2006; 451 (Suppl.): 30-38.
22. Möhrenschlager M, Schäfer T, Huss-Marp J et al. The course of eczema in children aged 5-7 years and its relation to atopy: Differences between boys and girls. Br J Dermatol 2006; 154: 505-513.
23. Banikazemi M, Bultas J, Waldek S et al. Agalsidase-beta therapy for advanced Fabry disease. Arch Intern Med 2007; 146: 77-86.
24. Oshima T, Murray GJ, Swaim WD et al. α-Galactosidase A deficient mice: A model of Fabry disease. Proc Natl Acad Sci USA 1997; 94: 2540-2544.